arrow
R

Roberto Iacovelli

fondazione policlinico universitario agostino gemelli
H指数:45
被引数:8,123

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

新辅助尼沃鲁单抗联合或不联合维苏格罗单抗治疗肌层浸润性膀胱癌:GDFATHER-NEO 2a期试验

2026-10-240
OAAI
34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

34 Belzutifan联合仑伐替尼与卡博替尼在PD-(L)1后肾细胞癌中的比较:LITESPARK-011 III期研究中健康相关生活质量结局

2026-09-020
OAAI
66 Relationship Between Health-related Quality of Life and Efficacy in the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in Previously Treated Advanced Clear Cell Renal Cell Carcinoma

66 健康相关生活质量与疗效在LITESPARK-005研究(比较Belzutifan与Everolimus在先前治疗过的晚期透明细胞肾细胞癌中的效果)第三阶段的关系

2026-09-020
OAAI
57 Final Analysis of the TiNivo-2 Phase 3 Trial: Long-term Outcome of Tivozanib (Tivo) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

57 TiNivo-2 III期试验的最终分析:替沃扎尼(Tivo)在转移性肾细胞癌(mRCC)患者中的长期结局

2026-09-020
OAAI
1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022

1 帕博利珠单抗联合贝舒妥昔单抗与帕博利珠单抗联合安慰剂作为肾细胞癌辅助治疗:LITESPARK-022研究中的患者报告结局

2026-09-020
OAAI
A Narrative Review of da Vinci Single-Port Versus Multi-Port Robotic Surgery in Elderly or Frail Urological Cancer Patients

达芬奇单端口与多端口机器人手术在老年或虚弱泌尿系统癌症患者中的叙事性综述

Cancers
IF4.4
2026-08-010
OA
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling

通过血浆谱分析确定的癌症免疫治疗结果的代谢决定因素

2026-06-250
OAAI
Correction: Schubert et al. Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery. Life 2026, 16, 73

更正:Schubert等人. 肾细胞癌患者微创消融策略,适用于不适合手术的患者。Life 2026, 16, 73

Life
IF3.4
2026-05-290
OAAI
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions

液体活检在非转移性前列腺癌中的应用:临床证据与未来方向

Cancers
IF4.4
2026-03-010
OAAI
Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery

肾细胞癌患者微创消融策略(不适用于手术的患者)

Life
IF3.4
2026-01-040
OAAI
A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease

非转移性前列腺癌的新型综合基因组图谱分析:使用FPG500检测代表疾病进展的可操作突变的研究方案

2025-10-100
PRE
Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)

tivozanib (TIVO) 治疗肾细胞癌 (RCC) 的综合疗效与安全性暴露反应 (ER) 分析

2025-10-010
OAAI
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey

指导晚期尿路上皮癌一线治疗决策:一项全球调查

2025-10-010
OAAI
Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC)

tivozanib (tivo) 在转移性肾细胞癌 (mRCC) 患者中 III 期临床试验的安全性概述

2025-10-010
OAAI
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis

评估内脏疾病患者中转移性激素敏感性前列腺癌的治疗效果:一项系统评价和网络Meta分析

2025-07-100
OAAI